Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer

New reliable biomarkers are needed to predict the response to immune checkpoint inhibitors against programmed death-1 (PD-1) and its ligand (PD-L1), because PD-L1 expression on tumor cells has limited power for selecting patients who may benefit from such therapy. Here we investigated the significan...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Yusuke, Yoshimura, Katsuhiro, Mori, Kazutaka, Kurabe, Nobuya, Kahyo, Tomoaki, Mori, Hiroki, Kawase, Akikazu, Tanahashi, Masayuki, Ogawa, Hiroshi, Inui, Naoki, Funai, Kazuhito, Shinmura, Kazuya, Niwa, Hiroshi, Suda, Takafumi, Sugimura, Haruhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078001/
https://www.ncbi.nlm.nih.gov/pubmed/27050074
http://dx.doi.org/10.18632/oncotarget.8528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078001/
https://www.ncbi.nlm.nih.gov/pubmed/27050074
http://dx.doi.org/10.18632/oncotarget.8528

Ejemplares similares